Heart & Vascular Research & Innovation Center
Clinical Research Studies
A sample of the clinical research studies in progress within our center include:
- Renal Denervation: For patients with hypertension (high blood pressure), UH Harrington Heart & Vascular Institute has launched a clinical research study to evaluate the potential benefits of an investigative device-based intervention to help lower blood pressure. The procedure being tested is called renal denervation.
- Transcatheter Aortic Valve Replacement (TAVR): For patients with aortic stenosis who are at high or extreme risk for surgical aortic valve replacement, transcatheter aortic valve replacement (TAVR) is an effective option. UH Harrington Heart & Vascular Institute cardiologists are among the first in the country to use a fully percutaneous, conscious sedation approach for TAVR. What was previously major open-heart surgery is now being performed on an awake and talking patient with excellent results. The Interventional Cardiovascular Center of UH Harrington Heart & Vascular Institute is recognized as a high-volume Center of Excellence and is now a training center for the minimalist, percutaneous conscious sedation TAVR approach.
- Left Ventricular Parachute: Following anterior myocardial infarction (MI), some patients develop adverse left ventricular remodeling that results in left ventricular (LV) dilation, antero-apical aneurysm formation and heart failure. Patients with severe heart failure (Class III – IV) refractory to optimal medical therapy, including cardiac resynchronization therapy, may be candidates for the Parachute™ Ventricular Partitioning Device by CardioKinetix. The device partitions the antero-apical aneurysm, restoring optimal LV volume and geometry. UH Harrington Heart & Vascular Institute at UH Cleveland Medical Center is a leading enrolling center for the implantation of this investigational device percutaneously through the femoral artery.
- Regenerative Medicine Approaches for Heart and Vascular Disease: Researchers are investigating the use of adult stem cell transplant for patients with severe coronary artery disease (CAD), heart failure with reduced ejection fraction (HFrEF) or advanced peripheral arterial disease (PAD). Two trials, Revive CLI and MarrowStimTM PAD Kit IDE, involve the use of autologous adult stem cells to help the body enhance blood flow in the legs. Results from these trials may provide a promising alternative for patients who are facing amputation and have no other options. UH Harrington Heart & Vascular Institute is also participating in an adult stem cell trial for heart failure using adipose-derived stems obtained from a liposuction procedure to enhance myocardial performance.